tbuckley/cabot-search huggingface dataset:
PATHOGENY OF ADDISON'S DISEASE.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Endocrine System
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increase in Reported Prevalence of Microcephaly in Infants Born to Women Living in Areas with Confirmed Zika Virus Transmission During the First Trimester of Pregnancy — Brazil, 2015
Authors: Wanderson Kleber de Oliveira, Juan Cortez-Escalante, Wanessa Tenório Gonçalves Holanda De Oliveira, Greice Madeleine Ikeda do Carmo, Cláudio Maierovitch Pessanha Henriques, Giovanini Evelim Coelho, Giovanny Vinícius Araújo de França
Journal: MMWR Morbidity and Mortality Weekly Report (2016)
Some Metabolic Effects of Ovine Prolactin in Man
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hodgkin Lymphoma
Authors: Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, Richard F Ambinder, Celeste M Bello, Philip J Bierman, Kristie A Blum, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I Gordon, Francisco J Hernandez-Ilizaliturri, Ephraim P Hochberg, David G Maloney, David Mansur, Peter M Mauch, Monika Metzger, Joseph O Moore, David Morgan, Craig H Moskowitz, Matthew Poppe, Barbara Pro, Lawrence Weiss, Jane N Winter, Joachim Yahalom
Journal: Journal of the National Comprehensive Cancer Network (2011)
Acknowledgment Error
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A review of clinical endpoints and use of quality-of-life outcomes in phase III metastatic breast cancer clinical trials.
Authors: Raman Tatla, Denis Landaverde, Charles Victor, David Miles, Sunil Verma
Journal: Journal of Clinical Oncology (2012)

129 Background: The management of metastatic breast cancer (MBC) is often considered to be palliative, with most interventions intended to relieve disease symptoms, minimize treatment effects and prolong patient survival. The impact of disease and treatment on a patient's funcitonal abilities has led to an emphasis of incorporating quality of life (QoL) measures into clinical trials. The main objective of this study is to evaluate phase III clinical trials in MBC, and assess the inclusion of QOL as an endpoint, in addition to conventional efficacy endpoints. Methods: A structured PubMed search was conducted to identify phase III clinical trials published between Jan. 1990 and Aug. 2011, evaluating systemic treatment in MBC patients. Data pertaining to treatment regimens, study endpoints and clinical findings were collected, with a particular focus on progression-based (PB), overall survival (OS), and QoL endpoints. Results: Of 520 publications identified, 122 phase III MBC clinical trials met the inclusion criteria. Of these studies, 98.4% and 95.9% included PB and OS respectively, as clinical endpoints, while QoL was assessed in only 46 (37.7%) studies. While the inclusion of QoL was not associated with the significance of PB results, there was an association between the inclusion of QoL and OS results, with 59% of significant OS studies and 32% of non-significant OS studies including QoL as a clinical endpoint (p=0.016). When stratified by treatment arm, it was found that studies favouring standard therapy were more likely to include QoL (75%, p=0.045), compared to those favouring the intervention (56%), and those without significant differences (32%). Conclusions: Although the importance of QoL is often emphasized in MBC management and treatment decisions, only one-third of identified phase III clinical trials included an assessment of QoL. About half of these trials showed no statistically significant differences in the QoL endpoint; of not, instruments of varying validity were utilized. There needs to be a greater emphasis on the evaluation of QoL, with the use of standard and validated QoL tools in MBC clinical trials, especially as we increasingly focus on progression-based endpoints.
Health-Related Aspects of Integrated Pest Management
Authors: Ray F. Smith, Donald J. Calvert
Journal: Environmental Health Perspectives (1976)

Basic concepts and philosophy of integrated pest management are presented in order to dispel several misconceptions and to provide the necessary background information for discussion of its relationship to the health-related effects of pesticide use. Implications for human health of current pesticide practices in Central America are examined to illustrate major problems associated with the injudicious use of insecticides, i.e., human pesticide poisonings, development of insect resistance, and persistence in the environment. Mitigation of these problems would ideally be achieved through the efforts and cooperation of a multidisciplinary team of scientists and technical people in the medical and agricultural sciences. The dilemma associated with the development of integrated pest control systems in developing countries is discussed. The FAO/UNEP Global Programme was reviewed.
Painful ophthalmoplegia from metastatic nonproducing parathyroid carcinoma: Case study and review of the literature
Authors: M. Eurelings
Journal: Neuro-Oncology (2002)

Parathyroid carcinoma is an uncommon malignancy.Of the fewer than 400 cases reported, most have been cases of producing parathyroid carcinoma with accompanying hypercalcemia.Only 13 patients with nonproducing parathyroid carcinoma have been described.Nine of these 13 patients had metastatic disease.We report a patient with i.c.metastasis.Distal metastases of producing parathyroid carcinoma are treated surgically to prolong survival and prevent complications of hyperparathyroidism and hypercalcemia.One half of the patients with producing parathyroid carcinoma die within 5 years, mostly because of the complications of hypercalcemia.Nonproducing parathyroid carcinoma compares unfavorably with producing parathyroid carcinoma in terms of tumor progression and prognosis.Few data on choice of therapy in nonproducing parathyroid carcinoma are available.We treated our patient with a combination of radiotherapy and chemotherapy.Treatment was followed by an unexpectedly prolonged survival of 31 months after diagnosis of metastatic disease.Neuro-Oncology 4, 44-48, 2002 (Posted to Neuro-Oncology [serial online], Doc.01-023, October 3, 2001.URL <neuro-oncology.mc.duke.edu>)W e report a patient who had nonproducing parathyroid carcinoma with painful ophthalmoplegia from i.c.metastasis.We treated this patient with cranial radiotherapy (5 3 400 cGy in 1 week) followed by 3 cycles of chemotherapy once every 3 weeks, with a combination of cisplatin (100 mg/m 2 on day 1) and etoposide (120 mg/m 2 on days 1, 2, and 3).In view of the extreme rarity of the tumor, clinical trials to test different treatment modalities are not feasible.Therefore, the development of future treatment strategies depends on anecdotal reports.
A New Way To Reverse Excessive Blood Thinning from Warfarin
Journal: Annals of Internal Medicine (2002)

Summaries for Patients3 December 2002A New Way To Reverse Excessive Blood Thinning from WarfarinSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-11-200212030-00004 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Warfarin is a drug that “thins the blood” by interfering with normal blood clotting. Doctors prescribe warfarin to prevent blood clots in the legs, lungs, heart, and brain. People who take warfarin need frequent blood tests to make sure that the extent of blood thinning is appropriate. If the blood is thinned too much, serious bleeding from the nose or lungs or in the urine and gastrointestinal tract can occur. Doctors use different methods to reverse excessive blood thinning (excessive anticoagulation) from warfarin. If the degree of thinning ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate.” It is in the 3 December 2002 issue of Annals of Internal Medicine (volume 137, pages 884-888). The authors are RAE Deveras and CM Kessler.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoReversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate Ruby Anne E. Deveras and Craig M. Kessler Metrics 3 December 2002Volume 137, Issue 11Page: I-41KeywordsBloodBlood coagulationBlood plasmaHematologic testsHemorrhageLungsThrombosisUrineVeinsVitamin K ePublished: 3 December 2002 Issue Published: 3 December 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract 4941: TTF1 negative in non small cell lung cancer adenocarcinoma: A prognostic factor
Authors: Juan F. Cordoba, Serafin Morales, Joel Veas, Alvaro Rodriguez, Noemi Reguart, Antonieta Salud
Journal: Cancer Research (2019)

Abstract BACKGROUND: Patients with thyroid transcription factor 1 (TTF1) negative lung adenocarcinoma (ADC) have been reported to have a worse prognosis and to lack epidermal growth factor receptor (EGFR) mutations. This study describes a series of sample tumors from patients with clinically confirmed lung cancer. METHODS: In all lung cancer patients diagnosed in the University Hospital of Lleida from January 2011 to December 2016, a real world data study of TTF1-negative ADC was performed, using TTF1 clone 8G7G3/1(DAKO®). Each patient’s clinical history, pathology specimens and molecular results were noted. Two hundred and thirty one patients with TTF1 positive lung ADC formed the control group. RESULTS: Twenty seven (27) patients were identified with ADC TTF1 negative (74% males). The media age was 66 years. The smoking history was as follows: 55,5% former, 29,6% ex smokers and 14,8% never smokers. The clinical stages were as follows: stage I or II (n = 3 [11%]), stage III (n = 4 [14,8%]) and stage IV (n = 20 [74%]). Patients’ mean survival was 7,6 vs 24,4 months in ADC TTF1 negative patients (P= 0,00001). Three hundred and thirty four (334) patients with ADC were found, TTF1 results were available in 258 (77,2%) cases, of them twenty-seven cases (10,4%) had TTF1 negative; when they were compared with the control group, TTF1 negative patients had overall shorter survival (P= 0,00001), regardless of whether patients were treated with radical or palliative intent: 34,4 vs 10, months P=0,00001 (radical treatment) and 14,6 vs 6,7 months P= 0,007 (palliative intent). EGFR mutations were less frequent (P= 0,046) in TTF-negative tumors 5,5% vs 25,3%. CONCLUSIONS: Patients with TTF1 negative NSCLC ADC, have worse overall survival regardless of treatment intention and a lower frequency of EGFR mutations. KEYWORDS: lung adenocarcinoma (ADC), non small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR), prognosis in thyroid transcription factor 1 negative (TTF1) adenocarcinoma. Citation Format: Juan F. Cordoba, Serafin Morales, Joel Veas, Alvaro Rodriguez, Noemi Reguart, Antonieta Salud. TTF1 negative in non small cell lung cancer adenocarcinoma: A prognostic factor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4941.
Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’
Authors: D.J. Slamon, P. Neven, S. Chia, G. Jerusalem, M. De Laurentiis, S. Im, K. Petrakova, G. Valeria Bianchi, M. Martín, A. Nusch, G.S. Sonke, L. De la Cruz-Merino, J.T. Beck, Y. Ji, C. Wang, U. Deore, A. Chakravartty, J.P. Zarate, T. Taran, P.A. Fasching
Journal: Annals of Oncology (2021)

The authors regret that at the time the article was published, Supplementary Table S2 contained errors. This has now been corrected. The authors would like to apologise for any inconvenience caused. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survivalAnnals of OncologyVol. 32Issue 8PreviewRibociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC). Here we present a new landmark in survival follow-up for a phase III cyclin-dependent kinases 4 and 6 inhibitor clinical trial in patients with ABC (median, 56.3 months). Full-Text PDF Open Access
Posters
Authors: I. Malagon, S. Burke, R. M. Grounds, M. Müller, J. Sticher, E. Schindler, G. Hempelmann, L. Mascia, E. G. McKeating, P. J. D. Andrews, A. Choyce, A. C. Beaumont, S. Field, L. Brazzi, O. Chiara, M. Segala, M. G. Turconi, P. Pelosi, D. Volpi, I. Lantieri, Y. M. Lee, P. H. Park, Y. Koh, C. M. Lim, P. Kiefer, P. Kosonen, J. Takala, B. Calvet, P. Trinh-Duc, P. Wintrebert, B. Albat, P. Colson, D. Gionis, Marina Kardara, J. Papadatos, K. Sinaniotis, A. B’Chir, M. R. Losser, M. Romieu, S. Beloucif, D. Payen, B. A. McKinley, C. L. Parmley, B. D. Butler, I. V. Krivtsova, I. V. Vasilenko, M. E. Vishnevsky, A. V. Vatasin, V. N. Shabalin, N. Alkis, Y. Ates, B. Saygin, F. Tüzüncr, T. S. Walsh, P. Hopton, A. Lee, G. Kostopanagiotou, K. Theodoraki, K. Mavrantonis, A. Prahalias, N. Vaos, L. Athanassiou, V. Smyrniotis, J. Papadimitriou, H. Rask, M. E. Crawford, S. L. Nielsen, C. Allerød, P. Carl, N. Foldager, M. B. Sørensen, C. Routsi, S. Zakynthinos, P. Kaltsas, V. Markaki, H. Bardouniotou, E. Zakynthinos, Ch. Roussos, A. Mas, F. Baigorri, D. Joseph, X. Calvet, P. Saura, L. I. Blanch, R. Fernández, A. Artigas
Journal: Intensive Care Medicine (1996)
Geriatric Endocrinology
Authors: S. Hontela
Journal: JAMA (1979)

One of the common obstacles that the reader of geriatric studies confronts is the lack of a common language: what is the age of a geriatric patient, what life-period has the author in mind when he speaks about aged, elderly, aging, and old persons. Data concerning blood pressure, body weight, and particularly blood concentrations of hormones when presented without a clearly defined life-period might lead to confusion. It is well known that bone loss is considerably lower in the elderly than in those in the early postmenopausal period. Anatole France, quoted by Greenblatt in the introduction, says, "we are already old when we are born"; but what has this statement to do with geriatric endocrinology or with the author's remark about man's age in the antediluvial era in which "Methusaleh lived 600 years, and Noah, surviving the flood, lived 900 years. The life span in the postdiluvial era is more
PHARMACOLOGY AT HOME AND ABROAD.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NECROLOGY.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chemotherapy of neuroblastoma
Authors: L. F. Sinks
Journal: JAMA (1968)

The treatment of neuroblastoma of childhood has long fascinated the physician and surgeon. Perhaps this is because of the vagary of the tumor. In spite of gloomy mortality figures, an appreciable number of cases have responded to some form of therapy, be it surgery, irradiation, and more recently, chemotherapy, and have survived. Moreover, cases of spontaneous remissions have been seen. This occasional happy outcome serves as a great stimulus to all concerned, but also leads to premature conclusions regarding the effectiveness of the therapeutic agent or agents being employed. Neuroblastoma represents approximately 12% of all childhood tumors, excluding the leukemias and lymphomas,<sup>38,39</sup>and in the not so distant past when no therapy was available, the average survival was quoted as ranging from eight weeks<sup>39</sup>to four months.<sup>40</sup>This universally hopeless picture changed considerably in 1940 when Farber<sup>41</sup>and Wyatt and Farber<sup>8</sup>published their series on